search
Back to results

Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study

Primary Purpose

Cataract

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
FEMTIS 313G IOL
Acrysof SN60WF IOL
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract focused on measuring IOL, Stability, FEMTIS IOL, Acrysof IOL, FLACS, Capsulotomy

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Minimum 40 years of age
  • Cataracta Senilis
  • Expected postoperative astigmatism ≤ 0.75 D (combination with FLACS AK is tolerated up to 1.25 D preoperative astigmatism)
  • IOL power calculation between +10.00 D and 27.00 D
  • Expected postoperative best-corrected visual acuity of logMAR +0.3 or better
  • If eligible, availability to undergo second eye surgery within 2 weeks of the first eye surgery
  • Willing and able to comply with scheduled visits and other study procedures
  • Signed informed consent.

Exclusion Criteria:

  • Traumatic cataract
  • Previous corneal surgery and/or reshaping
  • Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy)
  • Irregular astigmatism
  • History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)
  • Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen)
  • Extensive visual field loss (e.g., glaucoma, history of cerebral vascular accidents, etc.)
  • Extensive diabetic macular disease
  • Amblyopia, strabismus
  • Keratoconus
  • Pseudoexfoliation syndrome or other capsule or zonular abnormalities that could affect postoperative centration or tilt of the IOL
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
  • Cognitive, cerebral or concentration disorders (e.g. dementia, Parkinson, etc.)
  • Suturing of incision required at time of surgery
  • Complications during surgery of the first eye.

Sites / Locations

  • Maastricht University Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

FEMTIS IOL

Acrysof IOL

Arm Description

The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.

The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag

Outcomes

Primary Outcome Measures

Decentration:To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs
To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs

Secondary Outcome Measures

Rotation stability
To compare rotation stability between both IOls using retro-illumination slitlamp photographs
Tilt: To compare the amount of tilt between both IOls using Scheimpflug images
To compare the amount of tilt between both IOls using Scheimpflug images
Visual outcomes
Uncorrected (UDVA) and corrected (CDVA) distance visual acuity using ETDRS reading charts.

Full Information

First Posted
May 8, 2017
Last Updated
April 30, 2018
Sponsor
Maastricht University Medical Center
Collaborators
Oculentis
search

1. Study Identification

Unique Protocol Identification Number
NCT03152500
Brief Title
Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study
Official Title
A Randomised, Subject-masked Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
September 30, 2017 (Actual)
Study Completion Date
October 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Oculentis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.
Detailed Description
Cataract is a clouding of the crystalline lens which causes vision loss and blindness if untreated. Cataract surgery is the most frequently performed surgical intervention in medicine with an incidence of 880 surgeries per 100.000 population in 2010 amounting to a total number of over 160.000 surgeries per year in the Netherlands.1,3 The number of individuals with cataracts is predicted to reach 30 million by the year 2020.2 Due to aging of the general population this number of cataracts will only grow in the future. For the last decade conventional phacoemulsification cataract surgery (CPCS) is the dominant form of cataract surgery in developed countries, accounting for over 90 percent of these procedures.4 The basic phacoemulsification procedure has remained largely unchanged over the past 20 years, including a series of steps: creating corneal incision, capsulorhexis and lensfragmentation.4 Although highly successful, each of the steps mentioned above are created manually which affects the safety and effectiveness of the procedure. Since the first human eye was treated by femtosecond laser cataract surgery in 2008, the femtosecond-laser assisted cataract surgery (FLACS) became an innovative growing new technology in the world of cataract surgery.4-7 Femtosecond-lasers are capable of performing some of the most delicate and essential key steps during cataract surgery: capsulotomy, lens fragmentation, and corneal incisions. 'Automating' these steps and performing them with increased precision could lead to an improved quality of capsulotomy, easier lens fragmentation, and more precisely positioned corneal incisions, which in turn, lead to improved visual and refractive outcomes, a decrease in intra- and postoperative complication rates, and increased quality of life. In order to remove the crystallized human lens, a circular opening in the capsular lens bag, capsulotomy, needs to be created. After removing the lens an intraocular lens (IOL) can be inserted in the empty capsule bag. However, one of the factors affecting postoperative achieved visual acuity and refraction, is the behaviour of this IOL in the capsular bag. Preoperative measurements need to be obtained in order to calculate the required IOL. One of the challenges of these IOL calculations is determining exactly where in the eye the IOL will end up, the effective lens position (ELP). The position of the IOL is crucial for the IOL's general performance because it influences the postoperative IOL tilt, decentration, and posterior capsule opacification (PCO). Considering the anatomical variety between patients, the predictability of an individual's ELP remains an educated guess. The ELP, and therefore the amount of IOL tilt, decentration and PCO, of an IOL is mainly influenced by the interaction between the IOL and the lens capsule, especially during the time of capsule shrinkage. Theoretically, the positive optical effect of an IOL is lost when there is more than 7 degrees of tilt or more than 0.4 mm of decentration.8 Furthermore, studies have shown the effect of axial displacement of an IOL on refractive error. There is approximately 1.25 D change per millimetre of the IOL's longitudinal displacement.9 This reflects the importance of a stable and predictable ELP. As mentioned above, the anatomy of an individual's eye is unique and therefore, each ELP will be different when placing the IOL in the capsular bag. Therefore, a new lens type has been developed: the FEMTIS® FB-313 laser lens (FEMTIS-IOL, Oculentis). This IOL has a special haptic system and is designed to be clasped in the capsular bag opening and therefore, the ELP of this IOL is theoretically more stable and predictable, resulting in a higher predictability of refractive and visual outcomes. However, in order to provide as much stability as possible a (nearly) perfect capsulotomy is needed. Several comparative studies have shown that femtosecond-lasers produce a more precise, circular, reproducible, and better centered capsulotomy compared to conventional manual capsulorhexis.6-7 The combination between the femtosecond-assisted capsulotomy and the implantation of a FEMTIS-IOL in the capsular opening, could definitely contribute to the search of perfection in cataract surgery. In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
IOL, Stability, FEMTIS IOL, Acrysof IOL, FLACS, Capsulotomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FEMTIS IOL
Arm Type
Experimental
Arm Description
The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
Arm Title
Acrysof IOL
Arm Type
Active Comparator
Arm Description
The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
Intervention Type
Device
Intervention Name(s)
FEMTIS 313G IOL
Intervention Description
Haptic design that enclaves the capsulorrhexis
Intervention Type
Device
Intervention Name(s)
Acrysof SN60WF IOL
Intervention Description
IOL in the bag
Primary Outcome Measure Information:
Title
Decentration:To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs
Description
To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs
Time Frame
13 weeks/3months
Secondary Outcome Measure Information:
Title
Rotation stability
Description
To compare rotation stability between both IOls using retro-illumination slitlamp photographs
Time Frame
13 weeks/3months
Title
Tilt: To compare the amount of tilt between both IOls using Scheimpflug images
Description
To compare the amount of tilt between both IOls using Scheimpflug images
Time Frame
13 weeks/3months
Title
Visual outcomes
Description
Uncorrected (UDVA) and corrected (CDVA) distance visual acuity using ETDRS reading charts.
Time Frame
13 weeks/3months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Minimum 40 years of age Cataracta Senilis Expected postoperative astigmatism ≤ 0.75 D (combination with FLACS AK is tolerated up to 1.25 D preoperative astigmatism) IOL power calculation between +10.00 D and 27.00 D Expected postoperative best-corrected visual acuity of logMAR +0.3 or better If eligible, availability to undergo second eye surgery within 2 weeks of the first eye surgery Willing and able to comply with scheduled visits and other study procedures Signed informed consent. Exclusion Criteria: Traumatic cataract Previous corneal surgery and/or reshaping Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy) Irregular astigmatism History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen) Extensive visual field loss (e.g., glaucoma, history of cerebral vascular accidents, etc.) Extensive diabetic macular disease Amblyopia, strabismus Keratoconus Pseudoexfoliation syndrome or other capsule or zonular abnormalities that could affect postoperative centration or tilt of the IOL Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) Cognitive, cerebral or concentration disorders (e.g. dementia, Parkinson, etc.) Suturing of incision required at time of surgery Complications during surgery of the first eye.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rudy Nuijts, MD PhD
Organizational Affiliation
University Eye Clinic Maastricht, Maastricht University Medical Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Centre
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6202 AZ
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No IPD will be shared

Learn more about this trial

Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study

We'll reach out to this number within 24 hrs